Clinical Trial Update: Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety and efficacy of House Dust Mite Allergen Extract for allergic rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• House Dust Mite Allergen Extract (House dust mite allergen extract)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: House Dust Mite Allergy | Phase 4 | Status: COMPLETED